IV.1 Tamoxifen, a human carcinogen or the share of common risk factors?

European Journal of Cancer

Volumn 34, Issue SUPPL. 4, 1998, Pages

  Sasco, A J ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

HORMONE; ORAL CONTRACEPTIVE AGENT; TAMOXIFEN;

BREAST CANCER; CANCER REGISTRY; CARCINOGENICITY; CLINICAL TRIAL; CONFERENCE PAPER; ENDOMETRIUM CANCER; FEMALE; HUMAN; ORAL DRUG ADMINISTRATION; POSTMENOPAUSE; PRIORITY JOURNAL; RISK FACTOR;

EID: 0031690213     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0959-8049(98)00107-5     Document Type: Conference Paper

References (16)

1. International Agency for Research on Cancer. IARC Monographs on the evaluation of carcinogenic risks to humans. Vol. 66. Some pharmaceutical drugs. Lyon, International Agency for Research on Cancer, 1996.
2. Andersson M, Storm HH, Mouridsen HT. Carcinogenic effects of adjuvant tamoxifen treatment and radiotherapy for early breast cancer. Acta Oncol 1992, 31, 259-263.
3. Fisher B, Costantino JP, Redmond CJ, et al. Endometrial cancer in tamoxifen-treated breast cancer patients: findings from the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-14. J Natl Cancer Inst 1994, 86, 527-537.
4. Rutqvist LE, Johansson H, Signomklao T, Johansson U, Fornander T, Wilking N. Adjuvant tamoxifen therapy for early stage breast cancer and second primary malignancies. J Natl Cancer Inst 1995, 87, 645-651.
5. Rydén S, Fernö M, Möller T, et al. Long-term effects of adjuvant tamoxifen and/or radiotherapy. Acta Oncol 1992, 31, 271-274.
6. Stewart HJ, Forrest AP, Everington D, et al. Randomised comparison of 5 years of adjuvant tamoxifen with continuous therapy for operable breast cancer. Br J Cancer 1996, 74, 297-299.
7. Curtis RE, Boice JD, Shriner DA, Hankey BF, Fraumeni JF Jr. Second cancers after adjuvant tamoxifen therapy for breast cancer. J Natl Cancer Inst 1996, 88, 832-834.
8. Hardell L. Tamoxifen as risk factor for carcinoma of corpus uteri. Lancet 1988, 2, 563.
9. Hardell L. Pelvic irradiation and tamoxifen as risk factors for carcinoma of corpus uteri. Lancet 1988, 2, 1432.
10. Sasco AJ, Chaplain G, Amoros E, Saez S. Endometrial cancer following breast cancer: effect of tamoxifen and castration by radiotherapy. Epidemiology 1996, 7, 9-13.
11. Sasco AJ. Tamoxifen and menopausal status: risks and benefits. Lancet 1996, 347, 761.
12. van Leeuwen FE, Benraadt J, Coebergh JW, et al. Risk of endometrial cancer after tamoxifen treatment of breast cancer. Lancet 1994, 343, 448-452.
13. Lutz JM, Chouillet AM, Coleman MP. Endometrium cancer after tamoxifen treatment for breast cancer: a population-based case-control study. In XIX Réunion du Groupe pour l'Epidémiologie et l'Engregistrement du Cancer dans les pays de Langue Latine [abstract C23], Granada, 1994.
14. Mignotte H, Lesur A, Luporsi E, et al. Endometrial carcinoma (EC) in women with breast cancer (BC). Eur J Cancer 1997, 33, S205.
15. Cook LS, Weiss NS, Schwanz SM, et al. Population-based study of tamoxifen therapy and subsequent ovarian, endometrial, and breast cancers. J Natl Cancer Inst 1995, 87, 1359-1364.
16. Sasco AJ, Gendre I. Carcinogenicity of tamoxifen. In Kellen JA, ed. Beyond the antiestrogen. Boston, Birkhaüser Boston, 1996, 59-92.